CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

This study tests a new type of CAR-T cell therapy targeting both CD19 and CD20 proteins in patients with relapsed or treatment-resistant B-cell blood cancers including B-cell leukemia and B-cell lymphoma. **You may be eligible if...** - You have a confirmed B-cell blood cancer (leukemia or lymphoma) that is CD19 and/or CD20 positive - Your cancer has relapsed or stopped responding to standard treatments - Your performance status is reasonable (ECOG score 0–2) - You have measurable disease - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have significant heart problems (such as recent heart attack, atrial fibrillation, or poor heart pump function) - You have active graft-versus-host disease (GVHD) - You have severe lung disease - You have active hepatitis, HIV, or syphilis - You have an uncontrolled serious infection - You have a severe autoimmune disease or congenital immune deficiency - You are pregnant or breastfeeding, or plan to become pregnant within 12 months Talk to your doctor to see if this trial is right for you.